Adoptive Transfusion of Tolerance Dendritic Cells Prolongs the Survival of Cardiac Allograft: A Systematic Review of 44 Basic Studies in Mice△_Chinese Journal of Evidence-Based Medicine

Authors：

WU Wenqiao ¹ , SHAN Juan ¹ ,  LI Youping ^1,2 , LUO Lei ¹ , SUN Guixiang ¹ , ZHOU Yanni ¹ , YANG Tong ¹ , XIA Mengjuan ¹ , GUO Yingjia ¹ , FENG Li ¹

1. Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, Regenerative Medical Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China;2. Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, China;

Corresponding author：

LI Youping, Email: yzmylab@hotmail.com

Keywords：

Animal experiment; Tolerogenic DC; Adoptive transfusion; Cardiac allograft; Systematic review

DOI：

10.7507/1672-2531.20120224

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　Tolerogenic DCs (Tol-DCs), a group of cells with imDC phenotype, can stably induce T cells low-reactivity and immune tolerance. We systematically reviewed the adoptive transfusion of Tol-DCs induced by different ways to prolong cardiac allograft survival and its possible mechanism.
Method 　MEDLINE (1966 to March 2011), EMbase (1980 to March 2011), and ISI (inception to March 2011) were searched for identification of relevant studies. We used allogeneic heart graft survival time as endpoint outcome to analyze the effect of adoptive transfusion of Tol-DC on cardiac allograft. By integrating studies’ information, we summarized the mechanisms of Tol-DC in prolonging cardiac grafts.
Results 　Four methods were used to induce Tol-DC in all of the 44 included studies including gene-modified, drug-intervened, cytokine-induced, and other-derived (liver-derived amp; spleen-derived) DCs. The results showed that all types of Tol-DC can effectively prolong graft survival, and the average extension of graft survival time for each group was as follows: 22.02 ± 21.9 days (3.2 folds to control group) in the gene modified group, 25.94 ± 16.9 days (4.3 folds) in the drug-intervened groups, 9.00 ± 8.13 days (1.9 folds) in the cytokine-induced group, and 10.69 ± 9.94 days (2.1 folds) in the other-derived group. The main mechanisms of Tol-DCs to prolong graft survival were as follows: a) induceT-cell hyporeactivity (detected by MLR); b) reduce the effect of cytotoxic lymphocyte (CTL); c) promote Th2 differentiation; d) induce Treg; e) induce chimerism.
Conclusion 　For fully MHC mismatched allogeneic heart transplant recipients of inbred mouse, adoptive transfusion of Tol-DC, which can be gene-modified, drug-intervened, cytokine-induced, spleen-derived or liver-derived, can clearly prolong the survival of cardiac allograft or induce immune tolerance. Gene-modified and drug-induced Tol-DC can prolong graft survival most obviously. Having better reliability and stability than drug-induction, gene-modification is the best way to induce Tol-DCs at present. One-time intravenous infusion of 2 × 106 Tol-DC is a simple and feasible way to induce long-term graft survival. Multiple infusions will prolong it but increase the risk and cost. Adoptive transfusion of Tol-DC in conjunction with immunosuppressive agents may also prolong the graft survival time.

Citation： WU Wenqiao,SHAN Juan,LI Youping,LUO Lei,SUN Guixiang,ZHOU Yanni,YANG Tong,XIA Mengjuan,GUO Yingjia,FENG Li. Adoptive Transfusion of Tolerance Dendritic Cells Prolongs the Survival of Cardiac Allograft: A Systematic Review of 44 Basic Studies in Mice△. Chinese Journal of Evidence-Based Medicine, 2012, 12(12): 1432-1445. doi: 10.7507/1672-2531.20120224 Copy

1.	Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol, 2003, 21: 685.
2.	Jonas S, Ayigari V, Viera D, et al. Neuroprotection against cerebral ischemia. A review of animal studies and correlation with human trial results. Ann N Y Acad Sci, 1999, 890: 2-3.
3.	Macleod MR, O’Collins T, Howells DW, et al. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias. Stroke, 2004, 35: 1203-1208.
4.	Chun-tao Z, Juan S, Li F, et al. Effects of Immunosuppressive Drugs on CD4+CD25+ Regulatory T Cells: A Systematic Review of Clinical and Basic Research. Chin J Evid-based Med, 2010, 10(6): 740-748.
5.	李幼平, 唐勇, 李永胜, 等. 慢性移植物失功的器官特异性: 基于OPTN数据的分析. 中国循证医学杂志, 2008, 8(11): 972-979.
6.	Giannoukakis N, Bonham CA, Qian S, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther, 2000, 1(5 Pt 1): 430-437.
7.	Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol, 2002, 169(6): 3382-3391.
8.	Tiao MM, Lu L, Tao R, et al. Application of Recipient-Derived Dendritic Cells to Induce Donor-Speciﬁc T-Cell hyporesponsiveness. Transplant Proc, 2004, 36(5): 1592-1594.
9.	Tiao MM, Lu L, Tao R, et al. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg, 2005, 241(3): 497-505.
10.	Tao R, Wang L, Chen CH, et al. Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant, 2006, 25(3): 310-319.
11.	Xu DL, Liu Y, Tan JM, et al. Marked prolongation of murine cardiac allograft survival using recipient immature dendritic cells loaded with donor-derived apoptotic cells. Scand J Immunol, 2004, 59(6): 536-544.
12.	Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol, 2007, 178(9): 5480-5487.
13.	Zhang X, Li M, Min WP. Preventing immune rejection through gene silencing. Methods Mol Biol, 2010, 623: 357-371.
14.	Kaneko K, Wang Z, Kim SH, et al. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection. Gene Ther, 2003, 10(2): 143-152.
15.	Zhang M, Wang Q, Liu Y, et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med, 2004, 82(4): 240-249.
16.	Sun W, He X, Guo Z, et al. IL-12p40-overexpressing immature dendritic cells induce T cell hyporesponsiveness in vitro but accelerate allograft rejection in vivo: role of NK cell activation and interferon-gamma production. Immunol Lett, 2004, 94(3): 191-199.
17.	Sun W, Wang Q, Zhang L, et al. TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo. J Mol Med, 2002, 80(8): 514-523.
18.	Takayama T, Kaneko K, Morelli AE, et al. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation, 2002, 74(1): 112-119.
19.	Liang X, Lu L, Chen Z, et al. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation, 2003, 76(4): 721-729.
20.	Xiang J, Gu X, Qian S, et al. Graded function of CD80 and CD86 in initiation of T-cell immune response and cardiac allograft survival. Transpl Int, 2008, 21(2): 163-168.
21.	Sun W, Wang Q, Zhang L, et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation, 2003, 76(9): 1351-1359.
22.	Wang Q, Liu Y, Wang J, et al. Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol, 2006, 177(4): 2175-2185.
23.	Fu H, Song S, Liu F, et al. Dendritic cells transduced with SOCS1 gene exhibit regulatory DC properties and prolong allograft survival. Cell Mol Immunol, 2009 6(2): 87-95.
24.	Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol, 2000, 164(1): 161-167.
25.	Garrod KR, Chang CK, Liu FC, et al. Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival. J Immunol, 2006, 177(2): 863-868.
26.	Li B, Koide Y, Uchijima M, et al. Pretreatment of recipients with mitomycin-C-treated dendritic cells induces significant prolongation of cardiac allograft survival in mice. Transplant Proc, 2002, 34(8): 3426-3428.
27.	Huang YL, Wang YZ, Chen JB, et al. Prevention of acute and chronic allograft rejection by combinations of tolerogenic dendritic cells. Scand J Immunol, 2011, 73(2): 91-101.
28.	Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant, 2005, 5(2): 228-236.
29.	Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol, 2007, 178(11): 7018-7031.
30.	Emmer PM, van der Vlag J, Adema GJ, et al. Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation, 2006, 81(10):1451-1459.
31.	Su G, Zhao WZ, Chen JJ, et al. Pretreatment of donor dendritic cells with NBD-peptide prolongs mouse cardiac allograft survival. Journal of Southern Medical University, 2008, 28(9): 1562-1567.
32.	Han CH, Li HF, Wang YX, et al. The influence of mycophenolate mofetil upon the maturation and allostimulatory activity of cultured dendritic cell progenitors and the effects of tolerance induction in allograft recipients. National Medical Journal of China, 2005, 85(19): 1327-1332.
33.	Kaneko K, Morelli AE, Wang Z, et al. Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival. Clin Immunol, 2003, 108(3): 190-198.
34.	Zhang X, Li M, Lian D, et al. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol, 2008, 127(3): 313-321.
35.	Heng Y, Ma Y, Yin H, et al. Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transpl Int, 2010, 23(12): 1259-1270.
36.	Wang Q, Zhang M, Ding G, et al. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol Lett, 2003, 90(1): 33-42.
37.	Oh BC, Lee HM, Lim DP, et al. Effect of Immature Dendritic Cell Injection Before Heterotropic Cardiac Allograft. Transplantation Proceedings, 2006, 38: 3189-3192.
38.	Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation, 1996, 62(5): 659-665.
39.	Lu L, Li W, Zhong C, et al. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation, 1999, 68(6): 747-757.
40.	Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol, 2000, 30(7): 1813-1822.
41.	Hikawa H, Lotze MT, Rosenblum WD. Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model. Gen Thorac Cardiovasc Surg, 2007, 55(8): 307-314.
42.	Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation, 1997, 64(12): 1808-1815.
43.	Lan YY, Wang Z, Raimondi G, et al. "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol, 2006, 177(9): 5868-5877.
44.	O’Connell PJ, Li W, Wang Z, et al. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol, 2002, 168(1): 143-154.
45.	Niimi M, Shirasugi N, Ikeda Y, et al. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation, 2001, 72(9): 1556-1562.
46.	Gao JX, Madrenas J, Zeng W, et al. CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection. Immunology, 1999, 98(2):159-170.
47.	Wu W, Zheng N, Wang Y, et al. Immune regulatory activity of liver-derived dendritic cells generated in vivo. Microsurgery, 2006, 26(1): 17-20.
48.	Liang X, Chen Z, Fung JJ, et al. Regulatory dendritic cells modulate immune responses via induction of T-cell apoptotic death. Microsurgery, 2006, 26(1): 21-24.
49.	Abe M, Wang Z, de Creus A, et al. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant, 2005, 5(8): 1808-1819.

1. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol, 2003, 21: 685.
2. Jonas S, Ayigari V, Viera D, et al. Neuroprotection against cerebral ischemia. A review of animal studies and correlation with human trial results. Ann N Y Acad Sci, 1999, 890: 2-3.
3. Macleod MR, O’Collins T, Howells DW, et al. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias. Stroke, 2004, 35: 1203-1208.
4. Chun-tao Z, Juan S, Li F, et al. Effects of Immunosuppressive Drugs on CD4+CD25+ Regulatory T Cells: A Systematic Review of Clinical and Basic Research. Chin J Evid-based Med, 2010, 10(6): 740-748.
5. 李幼平, 唐勇, 李永胜, 等. 慢性移植物失功的器官特异性: 基于OPTN数据的分析. 中国循证医学杂志, 2008, 8(11): 972-979.
6. Giannoukakis N, Bonham CA, Qian S, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther, 2000, 1(5 Pt 1): 430-437.
7. Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol, 2002, 169(6): 3382-3391.
8. Tiao MM, Lu L, Tao R, et al. Application of Recipient-Derived Dendritic Cells to Induce Donor-Speciﬁc T-Cell hyporesponsiveness. Transplant Proc, 2004, 36(5): 1592-1594.
9. Tiao MM, Lu L, Tao R, et al. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg, 2005, 241(3): 497-505.
10. Tao R, Wang L, Chen CH, et al. Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant, 2006, 25(3): 310-319.
11. Xu DL, Liu Y, Tan JM, et al. Marked prolongation of murine cardiac allograft survival using recipient immature dendritic cells loaded with donor-derived apoptotic cells. Scand J Immunol, 2004, 59(6): 536-544.
12. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol, 2007, 178(9): 5480-5487.
13. Zhang X, Li M, Min WP. Preventing immune rejection through gene silencing. Methods Mol Biol, 2010, 623: 357-371.
14. Kaneko K, Wang Z, Kim SH, et al. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection. Gene Ther, 2003, 10(2): 143-152.
15. Zhang M, Wang Q, Liu Y, et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med, 2004, 82(4): 240-249.
16. Sun W, He X, Guo Z, et al. IL-12p40-overexpressing immature dendritic cells induce T cell hyporesponsiveness in vitro but accelerate allograft rejection in vivo: role of NK cell activation and interferon-gamma production. Immunol Lett, 2004, 94(3): 191-199.
17. Sun W, Wang Q, Zhang L, et al. TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo. J Mol Med, 2002, 80(8): 514-523.
18. Takayama T, Kaneko K, Morelli AE, et al. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation, 2002, 74(1): 112-119.
19. Liang X, Lu L, Chen Z, et al. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation, 2003, 76(4): 721-729.
20. Xiang J, Gu X, Qian S, et al. Graded function of CD80 and CD86 in initiation of T-cell immune response and cardiac allograft survival. Transpl Int, 2008, 21(2): 163-168.
21. Sun W, Wang Q, Zhang L, et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation, 2003, 76(9): 1351-1359.
22. Wang Q, Liu Y, Wang J, et al. Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol, 2006, 177(4): 2175-2185.
23. Fu H, Song S, Liu F, et al. Dendritic cells transduced with SOCS1 gene exhibit regulatory DC properties and prolong allograft survival. Cell Mol Immunol, 2009 6(2): 87-95.
24. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol, 2000, 164(1): 161-167.
25. Garrod KR, Chang CK, Liu FC, et al. Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival. J Immunol, 2006, 177(2): 863-868.
26. Li B, Koide Y, Uchijima M, et al. Pretreatment of recipients with mitomycin-C-treated dendritic cells induces significant prolongation of cardiac allograft survival in mice. Transplant Proc, 2002, 34(8): 3426-3428.
27. Huang YL, Wang YZ, Chen JB, et al. Prevention of acute and chronic allograft rejection by combinations of tolerogenic dendritic cells. Scand J Immunol, 2011, 73(2): 91-101.
28. Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant, 2005, 5(2): 228-236.
29. Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol, 2007, 178(11): 7018-7031.
30. Emmer PM, van der Vlag J, Adema GJ, et al. Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation, 2006, 81(10):1451-1459.
31. Su G, Zhao WZ, Chen JJ, et al. Pretreatment of donor dendritic cells with NBD-peptide prolongs mouse cardiac allograft survival. Journal of Southern Medical University, 2008, 28(9): 1562-1567.
32. Han CH, Li HF, Wang YX, et al. The influence of mycophenolate mofetil upon the maturation and allostimulatory activity of cultured dendritic cell progenitors and the effects of tolerance induction in allograft recipients. National Medical Journal of China, 2005, 85(19): 1327-1332.
33. Kaneko K, Morelli AE, Wang Z, et al. Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival. Clin Immunol, 2003, 108(3): 190-198.
34. Zhang X, Li M, Lian D, et al. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol, 2008, 127(3): 313-321.
35. Heng Y, Ma Y, Yin H, et al. Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transpl Int, 2010, 23(12): 1259-1270.
36. Wang Q, Zhang M, Ding G, et al. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol Lett, 2003, 90(1): 33-42.
37. Oh BC, Lee HM, Lim DP, et al. Effect of Immature Dendritic Cell Injection Before Heterotropic Cardiac Allograft. Transplantation Proceedings, 2006, 38: 3189-3192.
38. Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation, 1996, 62(5): 659-665.
39. Lu L, Li W, Zhong C, et al. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation, 1999, 68(6): 747-757.
40. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol, 2000, 30(7): 1813-1822.
41. Hikawa H, Lotze MT, Rosenblum WD. Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model. Gen Thorac Cardiovasc Surg, 2007, 55(8): 307-314.
42. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation, 1997, 64(12): 1808-1815.
43. Lan YY, Wang Z, Raimondi G, et al. "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol, 2006, 177(9): 5868-5877.
44. O’Connell PJ, Li W, Wang Z, et al. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol, 2002, 168(1): 143-154.
45. Niimi M, Shirasugi N, Ikeda Y, et al. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation, 2001, 72(9): 1556-1562.
46. Gao JX, Madrenas J, Zeng W, et al. CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection. Immunology, 1999, 98(2):159-170.
47. Wu W, Zheng N, Wang Y, et al. Immune regulatory activity of liver-derived dendritic cells generated in vivo. Microsurgery, 2006, 26(1): 17-20.
48. Liang X, Chen Z, Fung JJ, et al. Regulatory dendritic cells modulate immune responses via induction of T-cell apoptotic death. Microsurgery, 2006, 26(1): 21-24.
49. Abe M, Wang Z, de Creus A, et al. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant, 2005, 5(8): 1808-1819.

Chinese Journal of Evidence-Based Medicine

Adoptive Transfusion of Tolerance Dendritic Cells Prolongs the Survival of Cardiac Allograft: A Systematic Review of 44 Basic Studies in Mice△

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content